What drug class is probenecid, and how does it work as a uricosuric?
Probenecid is a uricosuric medicine. In practical terms, its job is to lower blood uric acid by increasing how much uric acid the kidneys remove in urine. It does this by affecting kidney transporters involved in uric acid reabsorption, which reduces uric acid returning to the bloodstream and increases urate excretion.
What is probenecid used for clinically?
Probenecid is used to treat gout in people who have under-excretion of uric acid (as opposed to those whose gout is mainly driven by overproduction). By lowering serum urate, it helps reduce flares over time and helps prevent recurrence.
How is probenecid different from other gout drugs?
Compared with urate-lowering alternatives:
- Xanthine oxidase inhibitors (like allopurinol/febuxostat) lower uric acid production.
- Probenecid is different because it mainly increases uric acid removal (uricosuric action).
Because of that difference, probenecid is generally considered in patients where increasing renal urate excretion is a better fit than blocking production.
What side effects or risks come with uricosuric drugs like probenecid?
Uricosurics can raise the amount of uric acid in urine. That increases the risk of kidney stones in some patients. Clinicians often manage this risk with adequate hydration and urine alkalinization strategies when appropriate.
Where does probenecid fit in drug interactions?
Probenecid is also known for affecting renal tubular secretion of certain drugs, so it can change levels of some medications. That interaction potential is one reason it has a reputation beyond gout treatment: it can alter how other drugs are cleared by the kidneys.
Is probenecid still used, or is it mainly historical?
Probenecid is still used as an urate-lowering option, but in many settings it is less commonly used than xanthine oxidase inhibitors because of patient selection issues (especially kidney stone risk and the need for functioning renal clearance).
Sources
No source links were provided in the prompt for DrugPatentWatch.com or other materials, so none are cited here.